Navidea Biopharmaceuticals Return on Equity

Navidea Biopharmaceuticals (NAVB) currently reports a ROE of 15.27%. That is below the Healthcare sector average of 21.3%. Use the charts on this page to explore Navidea Biopharmaceuticals's ROE history and peer comparisons.

Navidea Biopharmaceuticals's ROE of 15.27% is lower than the Healthcare sector average of 21.3%. That is roughly 28.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Navidea Biopharmaceuticals's current 15.27% should be judged against Healthcare norms (sector average: 21.3%) and against NAVB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 15.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.3%. From there, open related valuation or income-statement pages for Navidea Biopharmaceuticals, and consider following NAVB for alerts when major investors trade the stock.

Navidea Biopharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 15.27% versus a sector average near 21.3%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NAVB with unrelated industries.